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ABSTRACT 
Background: The high mortality rate in pulmonary carcinoma is a problem encountered in various 
countries, including Indonesia. According to WHO, there are 2.09 million people affected by lung 
cancer and 1.76 million deaths due to lung cancer worldwide. This study was aimed to determine the 
profile of lung adenocarcinoma patients with positive EGFR mutation. 
Methods: The study was descriptive study with cross-sectional approach using secondary data 
obtained from medical records of lung adenocarcinoma patients.  
Results: The present study revealed that lung adenocarcinoma was found higher in patients with age 
>40 years old (93.9%) compared to those with age <40 years old. It was also higher in male (66.7%) 
than in female patients. Most patients with lung adenocarcinoma were at the IIIB stage (42.4%). It 
was also reported that higher cases was found in patients with history of smoking more than 15 years 
(42.4%). Hemoptoe was the most reported clinical symptoms in patients with lung adenocarcinoma 
(87.9%). Lung adenocarcinoma was also observed higher in patients without family history of 
pulmonary adenocarcinoma (81.8%). Seventeen of 33 EGFR mutations (51.5%) were observed in 
exon 19 and fourteen (48.5%) were in exon 21.  
Conclusion: The most common EGFR mutation lung adenocarcinoma was observed in exon 19. 
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Introduction 
Lung cancer is the leading cause of cancer-related deaths worldwide. In the United States, 
lung cancer kills 160,000 people each year. The incidence of new cases of lung cancer in the United 
States ranks second only to breast cancer, which is estimated at 224,390 cases in 2016, or 
approximately 13% of all cancer diagnoses occur 158,080 deaths in 2016 is about 27% of all cancer 
deaths.
1,2 
The incidence of lung cancer in Indonesia tends to increase. Data and information center of 
the Ministry of Health showed that the incidence of lung cancer in the Cancer Hospital Dharmais in 
2013 ranks third after breast cancer and cervical cancer in the amount of 173 cases or 7% of all 
cancers and deaths from lung cancer by 65 cases or 12% of of all cancer deaths.
3
 The lung cancer is 
divided into small cell lung cancer (SCLC)/small cell carcinoma. SCLC occurs in 20% of all lung 
cancers. Although the cancer cells are small, the multiplication of these cells are obviously rapid and 
form large tumors that spread throughout the body. A typical histological picture is the dominance of 
small cells that are mostly filled by mucus with a distribution of chromatin without nucleoli. It is also 
called "oat cell carcinoma" because it looks like the grain of wheat. These small cells tend to 
congregate around small blood vessels resembling pseudoroset. Mitotic cells that are found in 
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abundance as well as necrosis. DNA segregation causes a dark color around the blood vessels. Non-
small cell lung cancer (NSCLC)/non-small cell carcinoma.
4–7
  
Methods 
This was a descriptive study with cross-sectional design depicting lung adenocarcinoma 
patient profile at Ibnu Sina Hospital Makassar based on secondary data in the medical record. The 
sampling technique was total sampling, all population of affordable met the inclusion criteria and did 
not meet the exclusion criteria will be taken into the sample. The inclusion criteria were patients with 
lung adenocarcinoma treated at Ibnu Sina hospital Makassar from 2017 to 2019. Technique 
enforcement of diagnosis performed by fine-needle aspiration biopsy (FNAB) and cytology where 
most of the pathology results found based cytology.  
Result 
Data for this study was collected from Ibnu Sina Makassar medical record, from 2017 to 2019 
and the total of patients with lung adenocarcinoma was 33 cases, mostly were male with age over 40 
years old.  Based on a history of smoking, most are up to 15 years smoking history. Most patients had 
a history of hemoptoe and weight loss meanwhile the patient stage when diagnosed were IIIA stage 
with WHO PS 1. 
      Table 1. Profile of patients with adenocarcinoma 
Characteristics N % 
Gender   
 Men 22 66.7 
 women 11 33.3 
Age   
 <40 years 2 6.1 
 > 40 years 31 93.9 
Smoking Status   
 Do not smoke 13 39.4 
 Smoke <15 Years 6 18.2 
 Smoke > 15 Years 14 42.4 
Clinical symptoms   
 Cough 23 69.7 
 Chest pain 19 57.6 
 Dyspnea 24 72.7 
 Weight loss 25 75.7 
 Hemoptoe 29 87.9 
Family History   
Negative  6 18.2 
 Positive 27 81.8 
Stadium    
 IIA 2 6.1 
 IIB 2 6.1 
 IIIA  7 21.2 
 IIIB  14 42.4 
 IV  8 24.2 
 
 10 
Publisher: Faculty of Medicine Universitas Muslim Indonesia 
Green Medical Journal, Vol.2 No.1 (April, 2020) 
PS WHO   
 1 19 57.6 
 2 14 42.4 
   
Table 2. Profile of patients with lung adenocarcinoma by pathology 
Characteristics N % 
How Decision   
 FNAB 13 39.4 
 cytology 20 60.6 
EGFR mutations   
 ex 19 17 51.5 
 ex 21 16 48.5 
Mutations Ex 21   
 L858R 10 58.8 
 L861Q 7 41.2 
 
 The sample profile of this study showed in Table 1. Based on gender, lung adenocarcinoma 
was more common in men (66.7%) than in women (33.7%). It was also more common in over 15 
years smoker (42.4%) than less 15 years of smoker and nonsmoker. The most common clinical 
symptom was hemoptoe (87.9%), followed by weight loss (75.7%) and dyspnea (72.7%). Mostly, 
sample age were over 40 years old (31 patients) equal to 93.9% and 57.6% were categorized as 
Prominent score WHO (WHO PS) 1.  
Based on table 2, the diagnosis of lung adenocarcinoma mostly by cytology evaluation (20 
cases), equivalent to 60.6% . EGFR Exon 19 mutation was more common than Exon 21 with  each 
percentage were  51.5% and 48.5%.  Exon 21 mutations occurred in 17 sample and the L858R type 
was  more than L861Q 10 with ratio 10 cases (58.8%) and 7 cases (41.2%). 
Discussion 
In the present study using 33 samples obtained based on secondary data from 2017 to 2019 in 
the RS. Ibnu Sina Makassar. Based on the results of descriptive profiles acquired gender research 
subjects more than sex males than females. By age, the samples generally aged over 40 years. This is 
consistent with research in Wulandari, 2017, which is the subject of research in general women and 
the age range of 50 years.
1,8,9
  
 This research subject is NSCLC patients who undergo positive EGFR mutation and patients 
dominate smokers than non-smokers. This is not following the IPASS study found that lung 
adenocarcinoma predominantly occurs in nonsmokers than smoker. Its study result also has the same 
with previous research, whre a group of nonsmokers patients tends to have positive EGFR 
mutation.
1,2,10
  
 Smoking is the cause of 85-90% of all lung cancer cases. A derivative of nicotine in cigarettes 
is carcinogenic. Lung cancer cells express all histological types of the nicotinic acetylcholine receptor. 
Nicotine activates signaling pathways in tumor cells and normal cells that inhibits apoptosis, so that 
the nicotine is involved in the pathogenesis of lung cancer as a mutagen and tumor promoter. Other 
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materials are associated with lung cancer include asbestos, exposure to radiation, arsenic, nickel, 
chromium, chloromethyl ether, and air pollutants. Scarring of the lungs is also associated with an 
increased risk of lung cancer.
5
  
 Most clinical symptoms are hemoptoe, weight loss and dyspnea. The clinical manifestations 
of lung cancer dependen on the location and extent of the tumor. Clinical symptoms arise signifies 
have an advanced stage of disease manifestations. Symptoms often appear cough (75%), weight loss 
(68%), shortness (58-68%), chest pain (45-49%), hemoptoe (29-35%), bone pain (25%), hot (15-
20%), SVCS (4%), dysphagia (2%), wheezing and stridor (2%).
1,4,5 
The whole sample of this study are patients with lung adenocarcinoma with EGFR positive 
mutation, and EGFR exon 19 was the most common type. In EGFR exon 21 type, L858R mutation 
was predominantly.  This study result was similar  previous to study done by Wulandari, IPASS and 
WJTOG3405.
1,2,10
 
Conclusions 
Lung adenocarcinoma patients in Ibnu Sina hospital Makassar mostly were male gender and 
smoker with the most common symptom arises is hemoptoe, followed by weight loss and dyspnea. 
The diagnosed mostly made up by cytology evaluation. Mutation of EGFR Exon 19 was the most 
common mutation found on this study. Because of its high mortality rate, should be performed the 
similar studies with a larger population and region. Based on these data it can be concluded that men 
and smokers have a high risk of becoming pulmonary adenocarcinoma with EGFR exon mutations 19. 
The data of this study was valuable to strengthen the preventive socialization of lung cancer. 
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